News

Menarini catches ADC fever
Enlarge image

BusinessItalyUK

Menarini catches ADC fever

30.10.2012 - Italian Menarini Group and Oxford Biotherapeutics want to jointly develop five antibody-based drugs. The deal is worth €800m.

„I am very pleased to announce this novel strategic alliance, which foresees the development and manufacture of up to five cancer treatment programmes and a total investment of €800m“, said Alberto Giovanni Aleotti, a member of the Board of Florence-based Menarini Group, on 29 October 2012. The ally comes from the UK. The biotech company Oxford Biotherapeutics (OBT) will contribute five of its about 25 antibody and antibody drug conjugate (ADC) programmes, each of which addresses a different cancer indication via a different novel oncology target. Menarini, however, brings in its clinical knowledge so that under the agreements of the collaboration, the Italian pharma corporation will lead the efforts in the manufacture and clinical development of each programme, while OBT will provide the proprietary cancer target, antibody and arming technologies.

The companies plan to work together for about 10 years. Once clinical proof of concept of one or the other programme has been achieved, OBT will complete the clinical development and commercialise these novel antibody-based products in North America and Japan, whilst Menarini will develop and commercialise the products in Europe, CIS, Asia and Latin America. Menarini’s fortitude comes a bit as a surprise because the pharma business has already burned its fingers in antibody-based drugs: Just 16 months ago a Phase III trial of abagovomab, a mouse anti-idiotype monoclonal antibody mimicking the CA-125 antigen found on ovarian cancer cells, could not fulfil the expectations raised in previous studies.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/menarini-catches-adc-fever.html

LicensingSwitzerland

30.08.2016 Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.15 SEK8.85%
  • HYBRIGENICS (F)0.94 EUR8.05%
  • IXICO (UK)31.50 GBP5.00%

FLOP

  • ARGEN-X (B)13.70 EUR-3.52%
  • VECTURA (UK)132.10 GBP-3.17%
  • SAREUM HOLDINGS (UK)0.72 GBP-2.70%

TOP

  • NORDIC NANOVECTOR (N)33.60 NOK34.9%
  • MOLMED (I)0.42 EUR27.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)6.15 SEK25.5%

FLOP

  • BIONOR PHARMA (N)0.42 NOK-22.2%
  • ACTIVE BIOTECH (S)12.20 SEK-18.4%
  • E-THERAPEUTICS (UK)11.50 GBP-14.1%

TOP

  • NICOX (F)10.31 EUR439.8%
  • SAREUM HOLDINGS (UK)0.72 GBP227.3%
  • GENMAB (DK)1095.00 DKK89.8%

FLOP

  • BB BIOTECH (D)44.55 EUR-82.4%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)96.20 GBP-71.7%

No liability assumed, Date: 31.08.2016